Mortier E - Search Results

1

Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy.

Gérard L, Galicier L, Boulanger E, Quint L, Lebrette MG, Mortier E, Meignin V, Oksenhendler E. Gérard L, et al. Among authors: mortier e. AIDS. 2003 Jan 3;17(1):81-7. doi: 10.1097/00002030-200301030-00011. AIDS. 2003. PMID: 12478072

2

Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.

Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Grabar S, et al. HIV Med. 2008 Apr;9(4):246-56. doi: 10.1111/j.1468-1293.2008.00554.x. HIV Med. 2008. PMID: 18366449 Free article.

3

Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.

Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M; FHDH-ANRS CO 4. Piketty C, et al. AIDS. 2008 Jun 19;22(10):1203-11. doi: 10.1097/QAD.0b013e3283023f78. AIDS. 2008. PMID: 18525266

4

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Dominguez S, Mortier E, Molina JM, de Truchis P. Delaugerre C, et al. Among authors: mortier e. AIDS. 2008 Sep 12;22(14):1809-13. doi: 10.1097/QAD.0b013e328307f24a. AIDS. 2008. PMID: 18690163

5

Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.

Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. Fontas E, et al. J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):206-14. doi: 10.1097/QAI.0b013e318190018c. J Acquir Immune Defic Syndr. 2009. PMID: 19131886

6

Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner.

Frange P, Meyer L, Jung M, Goujard C, Zucman D, Abel S, Hochedez P, Gousset M, Gascuel O, Rouzioux C, Chaix ML; ANRS PRIMO Cohort Study Group. Frange P, et al. PLoS One. 2013 Jul 9;8(7):e69144. doi: 10.1371/journal.pone.0069144. Print 2013. PLoS One. 2013. PMID: 23874894 Free PMC article.

7

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Krastinova E, et al. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. PLoS One. 2013. PMID: 23936509 Free PMC article.

8

Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.

Laanani M, Ghosn J, Essat A, Melard A, Seng R, Gousset M, Panjo H, Mortier E, Girard PM, Goujard C, Meyer L, Rouzioux C; Agence Nationale de Recherche sur le Sida PRIMO Cohort Study Group. Laanani M, et al. Among authors: mortier e. Clin Infect Dis. 2015 Jun 1;60(11):1715-21. doi: 10.1093/cid/civ171. Epub 2015 Mar 3. Clin Infect Dis. 2015. PMID: 25737374

9

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups. Frange P, et al. J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25885327

10

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufi D, Obadia M, Bernard L, Goujard C, Meyer L; ANRS PRIMO cohort. Krastinova E, et al. BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1. BMC Infect Dis. 2015. PMID: 25888386 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page